Polymyxin Resistance Testing Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Market Overview:

The Polymyxin Resistance Testing Market is forecasted to expand from USD 137 million in 2024 to approximately USD 230.16 million by 2032, reflecting a compound annual growth rate (CAGR) of 6.7% over the 2024–2032 period.

Market growth is being propelled by several critical factors, notably the escalating threat of antimicrobial resistance (AMR) and the increasing necessity for accurate diagnostic tools to detect polymyxin-resistant infections. As polymyxins represent last-line antibiotics for treating multidrug-resistant Gram-negative bacterial infections, the emergence of resistant strains has significantly heightened demand for effective resistance testing solutions. The healthcare industry's broader shift toward precision medicine and individualized treatment regimens has further supported the integration of advanced diagnostic technologies. Additionally, supportive government policies and initiatives aimed at mitigating AMR are expected to drive adoption and market expansion.

Market Drivers:

Growing Emphasis on Combating Antimicrobial Resistance (AMR):

Antimicrobial resistance continues to pose a serious global health challenge, prompting governments, healthcare providers, and research bodies to intensify efforts against resistant infections. With many conventional antibiotics losing efficacy against evolving bacterial strains, the role of resistance testing has become increasingly crucial. Polymyxin resistance testing, in particular, enables clinicians to detect resistant pathogens promptly and tailor treatment approaches, thereby minimizing the misuse of antibiotics and helping to address the broader AMR crisis. According to the Centers for Disease Control and Prevention (CDC), antimicrobial-resistant infections result in over 2.8 million illnesses and approximately 35,000 deaths annually in the United States alone.

Market Challenges:

High Cost of Advanced Diagnostic Solutions:

A major barrier to widespread adoption within the Polymyxin Resistance Testing Market is the significant cost associated with modern diagnostic technologies. Techniques such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and MALDI-TOF require considerable investment in laboratory infrastructure, equipment, and highly trained personnel. These financial demands can hinder implementation, particularly in lower-income countries and resource-limited healthcare environments. Therefore, there is an ongoing need for cost-effective, scalable diagnostic options that ensure broader access without compromising accuracy or quality.

Market Segmentation:

By Product:

Diagnostic Kits

Reagent Kits

Testing Panels

Instruments

Automated Systems

Antimicrobial Susceptibility Testing (AST) Systems

By Testing Methods:

Molecular Methods

PCR (Polymerase Chain Reaction)

Next-Generation Sequencing (NGS)

Culture-Based Methods

Disk Diffusion

Broth Microdilution

Others

MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight)

By End User:

Hospitals

Diagnostic Laboratories

Research Institutions

Others

Academic Institutes

Public Health Organizations

By Region:

North America:

U.S.

Canada

Mexico

Europe:

Germany

France

United Kingdom

Italy

Spain

Rest of Europe

Asia Pacific:

China

Japan

India

South Korea

Southeast Asia

Rest of Asia Pacific

Latin America:

Brazil

Argentina

Rest of Latin America

Middle East & Africa:

GCC Countries

South Africa

Rest of the Middle East and Africa

Key Market Participants:

Thermo Fisher Scientific

Mast Group

Liofilchem

Rosco Diagnostica A/S

bioMérieux SA

Meridian

Beckman Coulter

Becton Dickinson & Company

Accelerate Diagnostics, Inc.

Bruker

EUCAST

Generon S.p.A.